{"id":399226,"date":"2025-06-03T01:05:00","date_gmt":"2025-06-02T23:05:00","guid":{"rendered":"https:\/\/medizinonline.com\/delgocitinib-cream-first-topical-pan-jak-inhibitor-approved-in-switzerland\/"},"modified":"2025-06-03T02:46:15","modified_gmt":"2025-06-03T00:46:15","slug":"delgocitinib-cream-first-topical-pan-jak-inhibitor-approved-in-switzerland","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/delgocitinib-cream-first-topical-pan-jak-inhibitor-approved-in-switzerland\/","title":{"rendered":"Delgocitinib cream &#8211; first topical pan-JAK inhibitor approved in Switzerland"},"content":{"rendered":"\n<p><strong>In the phase III DELTA 1 and 2 studies, delgocitinib cream showed a rapid onset of efficacy &#8211; at week 16, half of the patients achieved a 75% improvement in HECSI. The results of the DELTA 3 extension study show that the therapeutic effects are stable in the long term and that the benefit-risk profile is good even with longer-term use. Delgocitinib cream is approved for all subtypes of chronic hand eczema in adults when topical corticosteroids are insufficient or unsuitable. It is an innovative treatment option that addresses an important treatment gap.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fdelgocitinib-cream-first-topical-pan-jak-inhibitor-approved-in-switzerland%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>In the phase III DELTA 1 and 2 studies, delgocitinib cream showed a rapid onset of efficacy &#8211; at week 16, half of the patients achieved a 75% improvement in&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fdelgocitinib-cream-first-topical-pan-jak-inhibitor-approved-in-switzerland%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":399230,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Moderate to severe chronic hand eczema  ","footnotes":"[{\"id\":\"5fd2a9ab-47f8-4f7b-8739-58f8744c9e42\",\"content\":\"At least mild symptoms were defined in the DELTA-3 study using the IGA-CHE score. With an IGA-CHE of 0\\\/1, the skin was considered (almost) symptom-free and from an IGA-CHE \\u22652, the 2\\u00d7 daily treatment was resumed. \"},{\"id\":\"112fccc4-666b-4cb5-94e3-44b2c55f867d\",\"content\":\"Statistically significant differences in the improvement in the HESD (Hand Eczema Symptom Diary) for itching and pain vs. baseline were observed with Anzupgo\\u00ae compared to the vehicle cream for a mean reduction in itching already on day 1 (0.75 vs. 0.32; p&lt;0.001) and for a mean reduction in pain on day 3 (0.98 vs. 0.58; p=0.001).\"},{\"id\":\"2738cdf8-0433-434b-8a42-265c4d498549\",\"content\":\"The proportion of patients with HECSI-75 response and the proportion of patients with a reduction in HESD for itching\\\/pain of \\u22654 points was maintained in DELTA 3 until week 52.\"},{\"id\":\"9987b0b2-5898-410e-8b16-3882ad83cd2c\",\"content\":\"The safety profile of Anzupgo\\u00ae was investigated in three clinical studies up to 16 weeks (DELTA 1&amp;2) and 52 weeks (DELTA 3). The safety profile of Anzupgo\\u00ae is consistent and comparable to vehicle cream, both at week 16 in DELTA 1&amp;2 and up to week 52 in DELTA 3.      \"}]"},"category":[11331,11340,11508,11406,11530,11442,11548],"tags":[82466,82468,19713,20571,22621,17569],"powerkit_post_featured":[],"class_list":["post-399226","post","type-post","status-publish","format-standard","has-post-thumbnail","category-allergology-and-clinical-immunology","category-dermatology-and-venereology","category-education","category-infectiology","category-market-medicine","category-pharmacology-and-toxicology","category-rx-en","tag-anzupgo-en","tag-delgocitinib-cream","tag-delta-en","tag-hand-eczema","tag-jak-inhibitor-en-2","tag-staphylococcus-aureus-en","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-03 08:04:17","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":399237,"slug":"creme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse","post_title":"Cr\u00e8me au delgocitinib - premier inhibiteur topique pan-JAK autoris\u00e9 en Suisse","href":"https:\/\/medizinonline.com\/fr\/creme-au-delgocitinib-premier-inhibiteur-topique-pan-jak-autorise-en-suisse\/"},"it_IT":{"locale":"it_IT","id":399197,"slug":"delgocitinib-crema-primo-inibitore-pan-jak-topico-autorizzato-in-svizzera","post_title":"Delgocitinib crema - primo inibitore pan-JAK topico autorizzato in Svizzera","href":"https:\/\/medizinonline.com\/it\/delgocitinib-crema-primo-inibitore-pan-jak-topico-autorizzato-in-svizzera\/"},"pt_PT":{"locale":"pt_PT","id":399243,"slug":"delgocitinib-creme-primeiro-inibidor-topico-pan-jak-autorizado-na-suica","post_title":"Delgocitinib creme - primeiro inibidor t\u00f3pico pan-JAK autorizado na Su\u00ed\u00e7a","href":"https:\/\/medizinonline.com\/pt-pt\/delgocitinib-creme-primeiro-inibidor-topico-pan-jak-autorizado-na-suica\/"},"es_ES":{"locale":"es_ES","id":399196,"slug":"crema-de-delgocitinib-primer-inhibidor-topico-pan-jak-autorizado-en-suiza","post_title":"Crema de delgocitinib: primer inhibidor t\u00f3pico pan-JAK autorizado en Suiza","href":"https:\/\/medizinonline.com\/es\/crema-de-delgocitinib-primer-inhibidor-topico-pan-jak-autorizado-en-suiza\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/399226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=399226"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/399226\/revisions"}],"predecessor-version":[{"id":402182,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/399226\/revisions\/402182"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/399230"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=399226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=399226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=399226"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=399226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}